Skip to main content
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. — Investor Relations & Filings

Ticker · SPRO ISIN · US84833T1034 LEI · 54930074G13LHWJT2323 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2019-02-08 Major Shareholding Noti…
Country US United States of America
Listing US SPRO

About Spero Therapeutics, Inc.

https://sperotherapeutics.com/

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. The company's primary mission is to address the significant unmet medical needs caused by antibiotic resistance. Its pipeline includes tebipenem HBr, an oral carbapenem antibiotic candidate for the treatment of complicated urinary tract infections (cUTIs), which has completed a Phase 3 trial. Spero Therapeutics leverages its expertise in chemistry and microbiology, alongside strategic partnerships, to advance its portfolio of innovative therapies for serious infections.

Recent filings

Filing Released Lang Actions
SC 13G/A
Major Shareholding Notification
2019-02-08 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or material definitive agreements by a company. The text describes the entry into a material definitive license agreement with Everest Medicines II Limited, including financial terms such as upfront payments and milestone payments. It also references press releases filed as exhibits. There are no comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). The document is not a transcript, proxy, or governance report. It is a regulatory announcement of a material contract and related events, fitting the category of Regulatory Filings (RNS). The document length (6626 characters) and content confirm it is a full Form 8-K report, not merely a brief announcement or certification. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2019-01-07 English
FORM 4 SUBMISSION
Director's Dealing
2019-01-02 English
FORM 4 SUBMISSION
Director's Dealing
2019-01-02 English
FORM 4 SUBMISSION
Director's Dealing
2019-01-02 English
FORM 4 SUBMISSION
Director's Dealing
2019-01-02 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.